<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617067</url>
  </required_header>
  <id_info>
    <org_study_id>CTRIAL-IE 19-33</org_study_id>
    <secondary_id>2020-000073-24</secondary_id>
    <secondary_id>CTRIAL-IE 19-33</secondary_id>
    <nct_id>NCT04617067</nct_id>
  </id_info>
  <brief_title>Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to&#xD;
      standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for&#xD;
      patients with advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label phase II multi-centre single arm study which proposes to test the&#xD;
      anti-tumour efficacy of paricalcitol, in combination with GEM/Nab-paclitaxel in patients with&#xD;
      advanced metastatic pancreatic cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 weeks from registration into the study</time_frame>
    <description>PFS is the percentage of patients free of progression at 24 weeks from registration into the study as determined by radiographic disease assessments per RECIST version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>18 months post last patient registered</time_frame>
    <description>Overall survival (OS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>18 months post last patient registered</time_frame>
    <description>Time to Treatment Failure (TTF) is defined as time from registration to discontinuation of therapy or add-on of new anti-cancer therapy for any reason (including death, progression and toxicity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour response rate Duration of response</measure>
    <time_frame>18 months post last patient registered</time_frame>
    <description>Confirmed tumour response rate as assessed by RECIST criteria version 1.1. Duration of response (DR) as assessed by RECIST criteria version 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>18 months post last patient registered</time_frame>
    <description>Incidence of adverse events reported and toxicity evaluation as per the NCI CTCAE version 5.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hypercalcaemia</measure>
    <time_frame>18 months post last patient registered</time_frame>
    <description>Incidence of hypercalcaemia</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label: Paricalcitol 12mcg once daily, orally every day of each 28 day cycle PLUS GEM (1000mg/m2) and Nab-paclitaxel (Abraxane®) (125mg/m2) on days 1, 8 and 15 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.</description>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine (GEM) and Nab-paclitaxel</intervention_name>
    <description>GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).</description>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained prior to any study-related procedures.&#xD;
&#xD;
          2. Incurable recurrent, locally advanced or metastatic pancreatic adenocarcinoma.&#xD;
&#xD;
          3. Histologically or cytologically confirmed pancreatic adenocarcinoma.&#xD;
&#xD;
          4. No prior chemotherapy for incurable, locally advanced unresectable or metastatic&#xD;
             pancreatic cancer. Patients may have received prior chemotherapy in the neo-adjuvant&#xD;
             or adjuvant setting provided they have a minimum treatment-free interval of 3 months.&#xD;
&#xD;
          5. At least one measurable lesion according to RECIST criteria (Version 1.1). Patients&#xD;
             with bone only disease are not eligible.&#xD;
&#xD;
          6. Aged 18 years or older&#xD;
&#xD;
          7. ECOG performance status 0 - 2&#xD;
&#xD;
          8. Adequate haematological, renal and hepatic function measured within 28 days prior to&#xD;
             commencing study:&#xD;
&#xD;
               -  Total bilirubin ≤ ULN (or ≤ 3 x ULN (≤ grade 2) for patients with liver&#xD;
                  involvement)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (≤&#xD;
                  grade&#xD;
&#xD;
                  1) (≤ 5 x ULN for patients with liver involvement by pancreatic cancer).&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) ≥ 30mL/min/1.73 m2 (≤ grade 2) for patients with&#xD;
                  serum creatinine levels above or below the institutional normal range. If using&#xD;
                  creatinine clearance, actual body weight should be used for calculating&#xD;
                  creatinine clearance (e.g., using the Cockroft-Gault formula). For patients with&#xD;
                  a Body Mass Index (BMI) &gt;30 kg/m2, lean body weight should be used instead.&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L.&#xD;
&#xD;
               -  Haemoglobin (Hb) ≥ 8 g/dL (≤ grade 2)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (≤ grade 1)&#xD;
&#xD;
               -  Corrected serum calcium of ≤ 2.9 mmol/L (≤ grade 1).&#xD;
&#xD;
          9. Life expectancy of at least 12 weeks.&#xD;
&#xD;
         10. Women of childbearing potential and sexually active males must agree to use highly&#xD;
             effective contraceptive measures. This applies from starting treatment until at least&#xD;
             6 months after the last study drug administration. The investigator or a designated&#xD;
             associate is required to advise the patient how to achieve an adequate birth control.&#xD;
             Highly effective contraception is defined in the study as methods that achieve a&#xD;
             failure rate of less than 1% per year when used consistently and correctly. Such&#xD;
             methods include:&#xD;
&#xD;
             i. Combined (oestrogen and progestogen containing) hormonal contraception associated&#xD;
             with inhibition of ovulation (oral, intravaginal, transdermal). ii. Progestogen-only&#xD;
             hormonal contraception associated with inhibition of ovulation (oral, injectable and&#xD;
             implantable). iii. Intrauterine device (IUD). iv. Intrauterine hormone-releasing&#xD;
             system (IUS). v. Bilateral tubal occlusion. vi. Successfully vasectomised partner.&#xD;
             vii. Sexual abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treated with other investigational drugs within 28 days or 5.5 half-lives of treatment&#xD;
             start; in addition, concurrent alternative (complementary) medications are excluded&#xD;
             within 28 days of treatment start.&#xD;
&#xD;
          2. Known brain metastases, unless previously treated and well-controlled for at least 2&#xD;
             months.&#xD;
&#xD;
          3. Dementia, altered mental status, or any other psychiatric condition that would&#xD;
             interfere with the patient's safety or informed consent&#xD;
&#xD;
          4. History of other malignancy other than pancreatic cancer. However, patients who have&#xD;
             been disease free from another malignancy for at least 5 years, or patients with a&#xD;
             history of resected non-melanoma skin cancer or successfully treated in situ cancer&#xD;
             and superficial bladder tumours (Ta, Tis, T1) are eligible.&#xD;
&#xD;
          5. Known history of hypercalcaemia.&#xD;
&#xD;
          6. Presence or history of symptomatic kidney stones in the last 5 years.&#xD;
&#xD;
          7. Active, clinically serious infections &gt; grade 2 (CTCAE v5.0).&#xD;
&#xD;
          8. Greater than or equal to grade 2 sensory or motor neuropathy&#xD;
&#xD;
          9. Uncontrolled intercurrent illness, including, but not limited to uncontrolled&#xD;
             bacterial, viral, or fungal infection(s) requiring systemic therapy, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia,&#xD;
             or social situation that would affect compliance with the requirements of this study.&#xD;
&#xD;
         10. GI tract disease resulting in an inability to take oral medications, malabsorption&#xD;
             syndrome, where previous surgical procedures affect absorption and uncontrolled&#xD;
             inflammatory bowel disease.&#xD;
&#xD;
         11. History of diseases known to be associated with calcium disorders, including: ongoing&#xD;
             hyperparathyroidism and Sarcoidosis.&#xD;
&#xD;
         12. Hypersensitivity to any of the excipients of gemcitabine, Nab-paclitaxel or&#xD;
             Paricalcitol.&#xD;
&#xD;
         13. Known vitamin D toxicity&#xD;
&#xD;
         14. Undergoing treatment with the following therapies and medications:&#xD;
&#xD;
               1. Concurrent use of drugs known to influence serum calcium such as thiazide&#xD;
                  diuretics, teriparatide (recombinant parathyroid hormone), calcitonin and&#xD;
                  multivitamin supplements containing &gt; 400 IU of vitamin D or calcium.&#xD;
&#xD;
               2. Current use of drugs which could influence bioavailability of paricalcitol (such&#xD;
                  as magnesium-containing antacids, bile-resin binders).&#xD;
&#xD;
               3. Current use of strong inhibitors of CYP3A4 or CYP2C8.&#xD;
&#xD;
               4. Current use of inducers of CYP3A4 or CYP2C8.&#xD;
&#xD;
               5. Phosphate related medicinal products.&#xD;
&#xD;
        Note:&#xD;
&#xD;
          -  Zoledronate or denosumab for patients with bone metastasis is allowed. Note patients&#xD;
             with bone only disease are not eligible.&#xD;
&#xD;
          -  Calcium intake is not restricted, but calcium supplementation is not permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Bryan Hennessy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaumont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tallaght University Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Dublin 24</state>
        <zip>D24 NR04</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Dublin 4</state>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Dublin 9</state>
        <zip>D09V2N0</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <zip>T12 DC4A</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <zip>V94 F858</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <zip>X91 ER8E</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

